Enteric Disease Testing Market Worth USD 5.86 Billion by 2035 | SNS Insider

The U.S. Enteric Disease Testing Market is projected to grow from USD 1.08 Billion in 2025 to USD 1.53 Billion by 2035, while Europe is expected to increase from USD 1.10 Billion to USD 1.56 Billion, driven by growing foodborne disease surveillance, laboratory automation, and adoption of multiplex molecular testing platforms.

Austin, United States, June 23, 2026 (GLOBE NEWSWIRE) — According to SNS Insider, the Enteric Disease Testing Market Size was valued at USD 4.08 Billion in 2025 and is projected to reach USD 5.86 Billion by 2035, expanding at a CAGR of 3.70% during 2026–2035. The growth of the Enteric Disease Testing Market is driven by the increasing prevalence of foodborne and waterborne diseases, rising demand for rapid pathogen detection, expanding adoption of multiplex molecular diagnostics, and growing investments in laboratory automation and disease surveillance programs worldwide.

Get a Sample Copy of the Enteric Disease Testing Market Report 2026–2035 @ https://www.snsinsider.com/sample-request/6236

Foodborne Disease Surveillance and Multiplex Molecular Diagnostics Drive Enteric Disease Testing Market Growth

The increasing incidence of foodborne and waterborne diseases globally remains one of the most significant growth drivers for the enteric disease testing market. Gastrointestinal infections continue to pose substantial public health challenges, particularly among children, elderly populations, and immunocompromised individuals. Growing concerns regarding antimicrobial resistance and outbreak management are increasing the importance of accurate and timely pathogen identification, driving demand for advanced diagnostic testing solutions across healthcare systems.

Leading Market Players Listed in this Report are:

• bioMérieux SA
• Cepheid (Danaher Corporation)
• Thermo Fisher Scientific Inc.
• Abbott Laboratories
• Roche Diagnostics GmbH
• Meridian Bioscience Inc.
• Luminex Corporation (DiaSorin)
• BD (Becton, Dickinson and Company)
• Quidel Corporation (QuidelOrtho)
• Hologic Inc.
• Seegene Inc.
• Qiagen NV
• Siemens Healthineers AG
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• Chembio Diagnostics Inc.
• Coris BioConcept SPRL
• BÜHLMANN Laboratories AG
• Savyon Diagnostics Ltd.
• CorisBioConcept SA

Segmentation Analysis:

By Disease

The Bacterial Enteric Disease segment dominated the Enteric Disease Testing Market in 2025, accounting for approximately 54.31% of total market revenue. The segment’s leadership is attributed to the high prevalence of bacterial gastrointestinal infections caused by pathogens, such as Salmonella, Campylobacter, Clostridium difficile, and E. coli. The Parasitic Enteric Disease segment is projected to witness the fastest growth during the forecast period. Expanding molecular diagnostic capabilities for Giardia lamblia, Cryptosporidium parvum, and Entamoeba histolytica, coupled with increasing awareness of parasitic infections among immunocompromised patients, are driving segment growth.

By Test Type

The immunoassay segment accounted for the highest market share of about 46.32% in 2025 due to extensive use of ELISA and lateral flow immunoassays for fast pathogen detection globally. The molecular segment will exhibit the highest CAGR in the coming years owing to the growing preference for multiplex PCR assays, which can detect more than 20 pathogens from one sample at a time.

By End-Use

The Hospitals segment accounted for around 42.11% of the market share in 2025 owing to severe cases of gastrointestinal infection that need to be treated in hospitals along with complete diagnosis, infection prevention, and quick decision-making. It is expected that the Diagnostics Laboratories segment will experience the highest growth rate in the forecast period due to the increasing network of reference laboratories.

Regional Insights:

North America dominated the global Enteric Disease Testing Market in 2025 owing to its advanced diagnostic infrastructure, extensive food safety monitoring systems, widespread adoption of molecular testing technologies, and high burden of foodborne illnesses.

The U.S. Enteric Disease Testing Market was valued at approximately USD 1.08 Billion in 2025 and is expected to reach approximately USD 1.53 Billion by 2035, growing at a CAGR of approximately 3.69%. The United States remains the largest global market due to CDC-reported foodborne disease incidence, strong public health surveillance programs, extensive laboratory automation, and broad adoption of multiplex gastrointestinal pathogen panels across hospitals and reference laboratories. The increasing use of multiplex gastrointestinal pathogen panels, syndromic testing solutions, and automated laboratory workflows continues to support Enteric Disease Testing Market growth across the United States.

The Europe Enteric Disease Testing Market is estimated to be USD 1.10 Billion in 2025 and is projected to reach USD 1.56 Billion by 2035, growing at a CAGR of 3.55% during 2026–2035. The Europe Enteric Disease Testing Market continues to benefit from stringent food safety regulations, comprehensive disease surveillance systems, and implementation of the EU In Vitro Diagnostic Regulation (IVDR). Germany leads regional growth owing to its strong clinical microbiology infrastructure, hospital laboratory networks, and increasing utilization of advanced molecular diagnostic technologies. Growing implementation of molecular diagnostic platforms and food safety monitoring programs continues to strengthen the Enteric Disease Testing Market across Europe.

The Asia-Pacific region is projected to be the fastest-growing market during the forecast period. Rapid urbanization, increasing foodborne disease burden, expanding healthcare infrastructure, and rising government investments in disease surveillance and food safety initiatives are accelerating market growth across China, India, Indonesia, Vietnam, and other emerging economies.

Purchase the Enteric Disease Testing Market Report, Including Market Size, Share, Competitive Analysis, Regional Forecasts, and Growth Opportunities Through 2035 @ https://www.snsinsider.com/checkout/6236

Recent Developments:

• 2024: Thermo Fisher Scientific introduced an advanced TaqMan Pathogen Detection Kit enabling simultaneous real-time PCR detection of multiple gastrointestinal bacterial and viral pathogens.
• 2024: Cepheid expanded its Xpert Gastrointestinal Panel portfolio with enhanced bacterial and parasitic pathogen coverage, strengthening comprehensive syndromic testing capabilities on the GeneXpert platform.

Exclusive Sections of the Report (The USPs):

• MULTIPLEX SYNDROMIC TESTING & PATHOGEN DETECTION ANALYSIS – helps you understand adoption trends for gastrointestinal multiplex panels, diagnostic performance benchmarks, pathogen coverage expansion, and testing workflow optimization strategies.
• FOODBORNE DISEASE SURVEILLANCE & OUTBREAK MANAGEMENT INSIGHTS – helps you evaluate public health monitoring programs, outbreak detection capabilities, pathogen tracking systems, and food safety surveillance initiatives driving testing demand.
• MOLECULAR DIAGNOSTICS & RAPID TESTING TECHNOLOGY BENCHMARKS – helps you assess advancements in PCR, multiplex molecular panels, point-of-care testing, and next-generation diagnostic platforms transforming enteric disease detection.
• ANTIMICROBIAL RESISTANCE DETECTION & CLINICAL DECISION SUPPORT TRACKER – helps you identify opportunities related to resistance gene detection, antibiotic stewardship programs, treatment optimization, and emerging resistance surveillance technologies.
• POINT-OF-CARE DIAGNOSTICS & DECENTRALIZED TESTING OPPORTUNITY ANALYSIS – helps you uncover growth potential in emergency departments, urgent care centers, primary care clinics, home-based testing, and telehealth-integrated diagnostic solutions.
• AI-ENHANCED SURVEILLANCE & DIGITAL HEALTH INNOVATION ASSESSMENT – helps you gauge the impact of artificial intelligence, predictive outbreak analytics, automated result interpretation, geographic disease monitoring, and integrated public health intelligence systems on the future of enteric disease testing.

Enteric Disease Testing Market Report Scope

Related Market Reports

Bloodstream Infection Testing Market Size & Growth 2026

Lyme Disease Testing Market Share & Trends 2026

Fecal Calprotectin Testing Market Size & Outlook 2026

Critical Care Diagnostics Market Growth & Analysis 2026

Syndromic Multiplex Diagnostics Market Size & Trends 2026

About Us:

SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.

CONTACT: Contact Us:
Rohan Jadhav - Principal Consultant
Phone: +1-315-961-9094 (US)
Email: [email protected]

Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. UKNewshour.com takes no editorial responsibility for the same.